ArticleMolecular cell2008
Structure of a BCOR corepressor peptide in complex with the BCL6 BTB domain dimer.
Article in Molecular cell, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 93 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
93 citing papers in PubMed, 168 citations in OpenAlex.
- A bivalent molecular glue linking lysine acetyltransferases to oncogene-induced cell death.Cell · 2026Article
- Design and synthesis of novelFuture medicinal chemistry · 2025Article
- Omics-Based Characterization of BTB Gene Family in T. aestivum, Reveals the Potential of TaBTB11/56/57/58 in Combined Heat and Drought Stress Regulation.Rice (New York, N.Y.) · 2025Article
- Raman spectroscopy and bioinformatics-based identification of key genes and pathways capable of distinguishing between diffuse large B cell lymphoma and chronic lymphocytic leukemia.Frontiers in immunology · 2025Article
- BCL6 Inhibitors Exhibit Therapeutic Effects on Breast Cancer Cells through the BCL6-STAT4 Pathway.Anti-cancer agents in medicinal chemistry · 2025Article
- BCL6 inhibition: a promising approach to prevent germinal center-driven allo-immune responses.Frontiers in immunology · 2025Review
- Recognition of BACH1 quaternary structure degrons by two F-box proteins under oxidative stress.Cell · 2024Article
- Specific radiation damage to halogenated inhibitors and ligands in protein-ligand crystal structures.Journal of applied crystallography · 2024Article
- Article
- Distinct Perception Mechanisms of BACH1 Quaternary Structure Degrons by Two F-box Proteins under Oxidative Stress.bioRxiv : the preprint server for biology · 2024Article
- The N-Terminal Part ofInternational journal of molecular sciences · 2023Article
- Discovery of anJournal of medicinal chemistry · 2023Article
- Study of the in Vivo Functional Role of Mutations in the BTB Domain of the CP190 Protein of Drosophila melanogaster.Doklady. Biochemistry and biophysics · 2023Article
- Discovery of OICR12694: A Novel, Potent, Selective, and Orally Bioavailable BCL6 BTB Inhibitor.ACS medicinal chemistry letters · 2023Article
- TBL1X: At the crossroads of transcriptional and posttranscriptional regulation.Experimental hematology · 2022Review
- Increased slow dynamics defines ligandability of BTB domains.Nature communications · 2022Article
- Discovering cell-active BCL6 inhibitors: effectively combining biochemical HTS with multiple biophysical techniques, X-ray crystallography and cell-based assays.Scientific reports · 2022Article
- BCL6, a key oncogene, in the placenta, pre-eclampsia and endometriosis.Human reproduction update · 2022Review
- Sibling rivalry among the ZBTB transcription factor family: homodimers versus heterodimers.Life science alliance · 2022Article
- A growth-based platform for detecting domain-peptide interactions in the cytoplasm of mammalian cells.Scientific reports · 2022Article
33 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
Abstract
The transcriptional corepressors BCOR, SMRT, and NCoR are known to bind competitively to the BCL6 BTB domain despite the fact that BCOR has no detectable sequence similarity to the other two corepressors. We have identified a 17 residue motif from BCOR that binds directly to the BCL6 BTB domain and determined the crystal structure of the complex to a resolution of 2.6 A. Remarkably, the BCOR BCL6 binding domain (BCOR(BBD)) peptide binds in the same BCL6 binding site as the SMRT(BBD) peptide despite the lack of any significant sequence similarity between the two peptides. Mutations of critical BCOR(BBD) residues cause the disruption of the BCL6 corepression activities of BCOR, and a BCOR(BBD) peptide blocks BCL6-mediated transcriptional repression and kills lymphoma cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.